论文部分内容阅读
目的:对肿瘤标志物联合检测卵巢恶性肿瘤的临床价值进行研究,为临床诊断提供更为科学的依据。方法:选取2014年1月~2015年6月在我院进行治疗的150例卵巢肿瘤患者。其中属于恶性肿瘤的患者有88例,属于良性肿瘤的患者有62例。另外,选取健康女性108例。分别对三组患者血清中的肿瘤标志物癌胚抗原、肿瘤相关物质及糖类抗原CA125进行联合检测。结果:恶性肿瘤组中患者的肿瘤标志物含量要明显高于良性肿瘤组和健康组,并且肿瘤标志物联合诊断的准确度要比单项肿瘤标志物的检测要高。结论:联合检测肿瘤标志物能够为医生早期诊断卵巢恶性肿瘤提供可靠依据,提高恶性肿瘤治愈率,延长患者生命,对卵巢恶性肿瘤的诊断具有特异性,值得临床推广和应用。
Objective: To study the clinical value of tumor markers in the detection of ovarian cancer and provide a more scientific basis for clinical diagnosis. Methods: A total of 150 patients with ovarian tumors who were treated in our hospital from January 2014 to June 2015 were selected. Of these, 88 were malignant and 62 were benign. In addition, 108 healthy women were selected. Three groups of patients in the serum tumor markers carcinoembryonic antigen, tumor-associated substances and carbohydrate antigen CA125 joint detection. Results: The tumor markers in malignant tumor patients were significantly higher than those in benign tumor and healthy subjects, and the diagnostic accuracy of tumor markers was higher than that of single tumor markers. Conclusion: The combined detection of tumor markers can provide a reliable basis for doctors to diagnose ovarian cancer in the early stage, improve the cure rate of malignant tumors and prolong the life of patients, which is specific to the diagnosis of ovarian malignant tumors and is worthy of clinical promotion and application.